New classification system for erectile dysfunction therapies

Journal of Andrology

Volumn 19, Issue 4, 1998, Pages 399-404

  Heaton, Jeremy ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE; PHENTOLAMINE; POTASSIUM CHANNEL AFFECTING AGENT; PROSTAGLANDIN; TESTOSTERONE; VASOACTIVE INTESTINAL POLYPEPTIDE;

COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT PLANNING;

HUMANS; IMPOTENCE; MALE; THERAPEUTICS; VASODILATOR AGENTS;

EID: 0031708594     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (26)

1. Bauer GE, Baker J, Hunyor SN, Marshall P. Side-effects of antihypertensive treatment: a placebo-controlled study. Clin Sci Mol Med (Suppl) 1978;4:341S-344S.
2. Bogoras NA. Uber die volle plastiche Weiderherstellung eines rum koitus fahigen Penis (Peniplastica totalis). Zentralbl Chir 1936;63: 1271.
3. Derogatis LR, Meyer JK, Dupkin CN. Discrimination of organic versus psychogenic impotence with the DSFI. J Sex Marital Ther 1976;2: 229-240.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
6. Gerstenberg TC, Metz P, Ottesen B, Fahrenkrug J. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992;147:1277-1279.
7. Heaton JPW. Neural and pharmacological determinants of erection. Int J Impot Res 1998; in press.
8. Heaton JPW, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997;9:115-121.
9. Heaton JPW, Morales A, Adams M, Johnston B, El-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45:200-203.
10. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukato JM, Raifer J. Nitric oxide and cyclic GMP formation upon electric field stimulation cause relaxation of corpus cavernosus smooth muscle. Biochem Biophys Res Commun 1990;170:843-850.
11. Karacan I, Scott FB, Salis PJ, Attia SL, Ware JC, Altinel A, Williams RL. Nocturnal erections, differential diagnosis of impotence, and diabetes. Biol Psychiatry 1977;12:373-380.
12. Laumann EO, Gagnon JH, Michael RT, Michaels S, eds. The Social Organization of Sexuality. Chicago: The University of Chicago Press; 1994.
13. Lue TF. Impotence: a patient's goal-directed approach to treatment. World J Urol 1990;8:67-74.
14. Morales A, Johnson B, Heaton JPW, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994;152:1115.
15. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ. A brief male sexual function inventory for urology. Urology 1995;46:697-706.
16. Padma-Nathan H. The efficacy and synergy of polypharmacotherapy in primary and salvage therapy of vasculogenic erectile dysfunction. Int J Implant Res (Suppl 2) 1990;257-258.
17. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
18. Porst H, Derouet H, Idzikowski M, Hess H, Knispel HH, Moll VKG, Netzer M, Six G, Steif CG, Vradelis V, Wetterauer U. Oral phentolamine (Vasomax) in erectile dysfunction - results of a German multicenter study in 177 patients. Int J Impot Res 1996;8:117.
19. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-94.
20. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49:822-830.
21. Stief CG, Holmquist F, Djamilian M, Krah H, Andersson KE, and Jonas U. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. J Urol 1992; 148:1437-1440.
22. Stief CG, Wetterauer U, Schaebsdau FH, Jonas U. Calcitonin gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients. J Urol 1991;146:1010-1014.
23. Thase ME, Reynolds CF III, Jennings JR, Frank E, Howell JR, Houck PR, Berman S, Kupfer DJ. Nocturnal penile tumescence is diminished in depressed men. Biol Psychiatry 1988;24:33.
24. Virag R. Intracavernous injection of Papaverine for erectile failure. Lancet 1982;2:938.
25. ™) a new oral treatment for erectile dysfunction (ED): an 8 week double-blind, placebo-controlled parallel group study. Int J Impot Res 1996;8:116(A70).
26. Wessells H, Hansen JG, Fucciarelli K, Dorr R, Levine N. Melanotropic peptide for the treatment of psychogenic erectile dysfunction: double blind placebo controlled crossover dosing study. J Urol 1997; 157:201.